50.11

0.32% 0.16

Supernus Pharmaceuticals Inc (SUPN)

Overview News Price History Option Chain Financials Why SUPN Down? Discussions Forecast

Supernus Pharmaceuticals Inc stock is traded at $50.11, with a volume of 460.03K. It is up +0.32% in the last 24 hours and up +0.40% over the past month. Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. Its diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company's products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, Osmolex ER, and others.

Previous Close:

$49.95

Open:

$50.63

24h Volume:

460.03K

Relative Volume:

0.64

Market Cap:

$2.89B

Revenue:

$718.95M

Net Income/Loss:

$-38.55M

P/E Ratio:

-73.27

EPS:

-0.6839

Net Cash Flow:

$45.99M

1W Performance:

-1.67%

1M Performance:

+0.40%

6M Performance:

+1.81%

1Y Performance:

+58.58%

1-Day Range:

$49.76

$51.03

1-Week Range:

$49.65

$52.37

52-Week Range:

$29.16

$59.68

Supernus Pharmaceuticals Inc Stock (SUPN) Company Profile

Name

Supernus Pharmaceuticals Inc

Sector

Healthcare (1110)

Industry

Drug Manufacturers - Specialty & Generic (83)

Phone

301-838-2500

Address

9715 KEY WEST AVENUE, ROCKVILLE, MD

Employee

778

Twitter

@Supernus_Pharma

Next Earnings Date

2024-11-04

Latest SEC Filings

SUPN's Discussions on Twitter

Compare SUPN vs TAK, ZTS, HLN, TEVA, UTHR

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
SUPN Supernus Pharmaceuticals Inc	50.11	2.92B	718.95M	-38.55M	45.99M	-0.6839
TAK Takeda Pharmaceutical Co Adr	17.85	57.12B	29.85B	776.90M	4.35B	0.2408
ZTS Zoetis Inc	121.11	49.56B	9.47B	2.67B	2.28B	6.0218
HLN Haleon Plc Adr	9.70	43.86B	14.54B	2.22B	2.58B	0.4871
TEVA Teva Pharmaceutical Industries Ltd Adr	31.77	35.89B	17.41B	1.43B	1.00B	1.2182
UTHR United Therapeutics Corp	578.54	25.06B	3.18B	1.33B	1.04B	27.90

Supernus Pharmaceuticals Inc Stock (SUPN) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Oct-09-25	Upgrade	Piper Sandler	Neutral → Overweight
Jul-30-25	Upgrade	Cantor Fitzgerald	Neutral → Overweight
Feb-19-25	Downgrade	Cantor Fitzgerald	Overweight → Neutral
Jan-06-25	Initiated	Cantor Fitzgerald	Overweight
Sep-11-24	Downgrade	Piper Sandler	Overweight → Neutral
Jan-03-23	Resumed	Jefferies	Buy
Dec-01-21	Resumed	Jefferies	Buy
Apr-13-21	Upgrade	Jefferies	Hold → Buy
Jun-16-20	Upgrade	Piper Sandler	Neutral → Overweight
Jun-15-20	Resumed	Jefferies	Hold
Nov-08-19	Downgrade	Berenberg	Buy → Hold
Nov-07-19	Downgrade	Stifel	Buy → Hold
Nov-06-19	Downgrade	Jefferies	Buy → Hold
Nov-12-18	Reiterated	B. Riley FBR	Buy
Jan-18-18	Reiterated	B. Riley FBR, Inc.	Buy
Dec-28-17	Reiterated	B. Riley FBR, Inc.	Buy
Dec-04-17	Upgrade	Janney	Neutral → Buy
Nov-08-17	Upgrade	Stifel	Hold → Buy
Oct-19-17	Initiated	FBR & Co.	Buy
Sep-19-17	Downgrade	Stifel	Buy → Hold
Jul-17-17	Downgrade	Piper Jaffray	Overweight → Neutral
Jul-14-17	Initiated	Janney	Neutral
Jun-01-17	Upgrade	Piper Jaffray	Neutral → Overweight
Jul-18-16	Downgrade	Northland Capital	Outperform → Market Perform
Jul-18-16	Downgrade	Piper Jaffray	Overweight → Neutral
Feb-08-16	Upgrade	Jefferies	Hold → Buy
Nov-05-15	Reiterated	Northland Capital	Outperform
Oct-28-15	Initiated	Northland Capital	Outperform

View All

Supernus Pharmaceuticals Inc Stock (SUPN) Latest News

Apr 13, 2026

MACD Signal: Is Supernus Pharmaceuticals Inc part of any major index2026 Year in Review & Free AI Powered Buy and Sell Recommendations - baoquankhu1.vn

Apr 13, 2026

Tudor Investment Corp ET AL Invests $1.43 Million in Supernus Pharmaceuticals - National Today

Apr 13, 2026

Apr 12, 2026

Supernus Pharmaceuticals Acquires NV-5138 (SPN-820) Compound from Navitor Pharmaceuticals in Asset Purchase Agreement - Minichart

Apr 08, 2026

Apr 07, 2026

Supernus enters into asset purchase agreement with Navitor - TipRanks

Apr 07, 2026

Supernus (SUPN) Acquires Key Assets from Navitor Pharmaceuticals - GuruFocus

Apr 07, 2026

Supernus Acquires NV-5138 Asset in New Agreement - TipRanks

Apr 07, 2026

Supernus Pharmaceuticals Inc Enters Asset Purchase Agreement With Navitor On April 1, 2026 - TradingView — Track All Markets

Apr 07, 2026

According to a document submitted to the U.S. Securities and Exchange Commission (SEC), Supernus Pharmaceuticals has reached an agreement to acquire the asset portfolio related to the candidate drug NV-5138 (also known as SPN-820). - Bitget

Apr 07, 2026

[8-K] SUPERNUS PHARMACEUTICALS, INC. Reports Material Event - Stock Titan

Apr 07, 2026

Apr 06, 2026

RSI Check: Is Supernus Pharmaceuticals Inc a stock for growth or value investorsWeekly Stock Recap & Comprehensive Market Scan Reports - baoquankhu1.vn

Apr 06, 2026

Apr 02, 2026